sorafenib,camrelizumab,rivoceranib
jiangsu hengrui pharmaceuticals,elevar therapeutics,bayer
['hcc', 'shr,1210,iii,310', 'apatinib', 'camrelizumab']
 shr-1210-iii-310 phs-iii at lb35 first positive phs-iii combo with anti-pdl1/tki camrelizumab/apatinib: orr 25% mpfs 5.6mo mos 22.1 mo-&gt; safety needs to be observed more options in 1st line hcc -&gt;approval by fda/ema? #livertwitter #hcc 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine